Evogene (NASDAQ:EVGN) Posts Earnings Results, Misses Estimates By $0.35 EPS

Evogene (NASDAQ:EVGN) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.35), Morningstar.com reports. The business had revenue of $0.19 million during the quarter. Evogene had a negative net margin of 1,193.65% and a negative return on equity of 36.13%.

Evogene stock remained flat at $$1.45 during trading on Friday. 99 shares of the company were exchanged, compared to its average volume of 7,761. Evogene has a one year low of $1.39 and a one year high of $3.32. The company has a 50-day moving average of $1.52. The company has a quick ratio of 9.88, a current ratio of 9.88 and a debt-to-equity ratio of 0.05.

Separately, ValuEngine upgraded shares of Evogene from a “hold” rating to a “buy” rating in a report on Thursday.

A number of institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC lifted its stake in Evogene by 13.7% in the first quarter. ARK Investment Management LLC now owns 286,748 shares of the biotechnology company’s stock worth $525,000 after acquiring an additional 34,626 shares during the last quarter. Delek Group Ltd. lifted its stake in Evogene by 4.2% in the first quarter. Delek Group Ltd. now owns 217,824 shares of the biotechnology company’s stock worth $397,000 after acquiring an additional 8,717 shares during the last quarter. Eidelman Virant Capital purchased a new position in Evogene in the second quarter worth approximately $102,000. Jane Street Group LLC purchased a new position in Evogene in the fourth quarter worth approximately $71,000. Finally, Meitav Dash Investments Ltd. lifted its stake in Evogene by 44.7% in the first quarter. Meitav Dash Investments Ltd. now owns 28,521 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 8,804 shares during the last quarter. Institutional investors own 33.61% of the company’s stock.

Evogene Company Profile

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.

Read More: What is Call Option Volume?

Earnings History for Evogene (NASDAQ:EVGN)

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.